Top Page
Sosei Group
(OTC:4565)
Sosei Group (4565) vs. iShares MSCI Japan ETF (EWJ)
Sosei Group Business Overview & Revenue Model
Sosei Group Earnings Call Summary
Sosei Group Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 28.70B | 28.84B | 12.77B | 15.57B | 17.71B | 8.84B |
| Gross Profit | 20.43B | 21.22B | 9.66B | 14.64B | 16.78B | 8.08B |
| EBITDA | -3.42B | 105.00M | -5.71B | 3.57B | 2.19B | 3.19B |
| Net Income | -6.14B | -4.84B | -7.19B | 382.00M | 1.02B | 1.48B |
Balance Sheet | ||||||
| Total Assets | 144.18B | 151.50B | 157.20B | 99.42B | 96.98B | 76.47B |
| Cash, Cash Equivalents and Short-Term Investments | 28.46B | 36.20B | 49.06B | 66.56B | 60.17B | 40.01B |
| Total Debt | 63.14B | 67.90B | 73.97B | 29.73B | 29.27B | 16.62B |
| Total Liabilities | 78.52B | 82.98B | 90.39B | 41.48B | 39.52B | 24.08B |
| Stockholders Equity | 65.66B | 68.52B | 66.81B | 57.94B | 57.47B | 52.38B |
Cash Flow | ||||||
| Free Cash Flow | -13.97B | -8.24B | -6.12B | 9.65B | 6.89B | 4.57B |
| Operating Cash Flow | -13.51B | -7.72B | -5.27B | 9.95B | 7.09B | 4.67B |
| Investing Cash Flow | -1.48B | -4.76B | -63.79B | 1.04B | 278.00M | -150.00M |
| Financing Cash Flow | -6.70B | -6.85B | 48.33B | -4.89B | 11.12B | 20.28B |
Sosei Group Technical Analysis
Sosei Group Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | ¥22.01B | -54.84 | ― | ― | -5.65% | -469.19% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ¥137.14B | -167.09 | -1.81% | ― | 13.78% | -110.02% | |
47 Neutral | ¥98.74B | -15.47 | ― | 2.18% | -0.16% | -802.20% | |
40 Neutral | ¥78.73B | -12.76 | -9.05% | ― | -1.96% | -64.18% | |
38 Underperform | ¥31.52B | -6.94 | ― | ― | -82.33% | 47.73% |
Sosei Group Corporate Events
Nxera Pharma has completed a tender offer to repurchase ¥5 billion in principal amount of its euro-yen denominated convertible bonds due 2028, paying a total of approximately ¥4.84 billion excluding accrued interest, based on a slight discount to face value. Following the transaction, ¥27 billion in principal amount of the convertible bonds remains outstanding, indicating a targeted balance-sheet action that may modestly reduce future potential dilution for shareholders while maintaining significant outstanding convertible debt.
The most recent analyst rating on (JP:4565) stock is a Hold with a Yen718.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
Nxera Pharma will regain full rights to its GPR52 agonist program for schizophrenia, including Phase 2–ready lead candidate NXE0048149, after Boehringer Ingelheim chose not to exercise its exclusive licensing option. The decision triggers the return to Nxera of all data and intellectual property generated under the collaboration and leaves the company free to pursue new strategic options, including a formal out‑licensing process in 2026, without affecting its current-period consolidated financial results.
NXE0048149, designed using Nxera’s NxWave discovery platform, has shown a highly favorable safety profile in Phase 1 studies, dose-proportional pharmacokinetics and pharmacodynamic evidence of engaging brain circuitry relevant to schizophrenia, supporting once‑daily dosing and continued development. With GPR52 expression linked to positive, negative and cognitive symptom domains, Nxera believes the program could offer a first‑in‑class treatment that addresses shortcomings of existing therapies, and management views the return of full rights as a strategic opportunity to partner the asset with a major pharmaceutical or specialized neuroscience company.
The most recent analyst rating on (JP:4565) stock is a Hold with a Yen858.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
Nxera Pharma Co., Ltd. has successfully completed its buyback and consent solicitation for its existing Euro-yen denominated convertible bonds due 2028. The company received the necessary electronic consents to approve an extraordinary resolution, allowing it to execute a supplemental trust deed and cancel a planned meeting. The tender offer was conducted with a total purchase price of ¥4,837,500,000, leaving ¥27,000,000,000 in principal amount of the bonds outstanding.
The most recent analyst rating on (JP:4565) stock is a Buy with a Yen1400.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
Nxera Pharma Co. Ltd announced the receipt of dividends amounting to JPY 8,193 million from its subsidiary, Nxera Pharma UK Limited. The dividend income of JPY 2,793 million will be recorded as non-operating income in the company’s non-consolidated financial statements for the fiscal year ending December 31, 2025, with no impact on its consolidated financial results.
The most recent analyst rating on (JP:4565) stock is a Buy with a Yen1400.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
Nxera Pharma Co., Ltd. has announced a buyback and consent solicitation for its existing convertible bonds due in 2028. The company aims to amend the terms of these bonds to reduce near-term redemption risk and secure liquidity for strategic growth investments. By removing bondholders’ early redemption options and conducting a tender offer up to ¥5 billion, Nxera seeks to maintain lower funding costs and avoid dilutive effects on shareholders.
The most recent analyst rating on (JP:4565) stock is a Hold with a Yen767.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
Nxera Pharma has announced the introduction of a new Employee Stock Ownership Plan (J-ESOP) for its employees residing in Japan, replacing the existing Restricted Share Unit Plan. This strategic move aims to enhance employee motivation and engagement by aligning their interests with the company’s performance, providing tax benefits, and reducing the concentration of share sales, thereby potentially increasing the company’s corporate value and market performance.
The most recent analyst rating on (JP:4565) stock is a Hold with a Yen767.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
Nxera Pharma Co., Ltd. announced a strategic restructuring to enhance its path to profitability by concentrating on high-value programs and reducing operating expenses. The company aims to achieve significant cost savings and streamline operations, including a 15% workforce reduction, to support its ambitious 2030 vision of achieving JPY50 billion in net sales and a 30% operating profit margin. This restructuring will focus on prioritized R&D programs, particularly in obesity and metabolic disorders, while utilizing AI technology to enhance drug discovery processes.
The most recent analyst rating on (JP:4565) stock is a Hold with a Yen767.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
Nxera Pharma reported significant advancements in its strategic focus on obesity and metabolic diseases during the third quarter of 2025, highlighted by the launch of a proprietary pipeline led by an oral GLP-1 agonist. The company also achieved key milestones in its collaborations, including a $10 million payment from AbbVie for neurological disease research, and presented promising Phase 1 trial results for its cancer immunotherapy candidate. Despite these operational successes, Nxera experienced a financial downturn with increased R&D expenses and a net loss of JPY 4,809 million, reflecting the company’s investment in future growth and the impact of a weaker yen.
The most recent analyst rating on (JP:4565) stock is a Hold with a Yen883.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.